InflaRx N.V. (IFRX) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Invivyd (IVVD) over the past year, gaining 4.1% versus a loss of 57.3%. Over five years, IFRX leads with a -38.1% price change compared with -97.8% for IVVD. InflaRx N.V. is the larger company by market cap ($225.5 million vs $206.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | IVVD |
|---|---|---|
| Share price | $1.53 | $0.7004 |
| Market cap | $225.47M | $206.45M |
| 1-day change | -1.92% | -3.87% |
| YTD return | +51.49% | -71.64% |
| 1-year return | +4.08% | -57.29% |
| 5-year return | -38.06% | -97.84% |
| EPS (TTM) | $-0.58 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $3.07 |
| 52-week low | $0.798 | $0.528 |
| Distance from 52-week high | -48.12% | -77.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +401.96% | +1327.76% |
| Average volume | 798.72K | 4.78M |
| Shares outstanding | 147.37M | 294.76M |
| Employees | 65 | 122 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed IVVD by 61.4 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Healthcare · Biotechnology · 65 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Healthcare · Biotechnology · 122 employees
IFRX vs IVVD FAQ
Which is bigger, InflaRx N.V. or Invivyd?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $225.47M compared with $206.45M for Invivyd (IVVD).
Which stock has performed better over the past year, IFRX or IVVD?
IFRX returned +4.08% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Invivyd in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.